These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8100421)

  • 1. Low-dose oral recombinant interferon-alpha A in patients with HIV-1 infection: a blinded pilot study.
    Sperber SJ; Gocke DJ; Haberzettl CA; Pestka S
    AIDS; 1993 May; 7(5):693-7. PubMed ID: 8100421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial.
    Kaiser G; Jaeger H; Birkmann J; Poppinger J; Cummins JM; Gallmeier WM
    AIDS; 1992 Jun; 6(6):563-9. PubMed ID: 1388878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous low-dose interferon-alpha therapy for HIV-related immune thrombocytopenic purpura.
    Northfelt DW; Charlebois ED; Mirda MI; Child C; Kaplan LD; Abrams DI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jan; 8(1):45-50. PubMed ID: 8548345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
    Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
    Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.
    Lane HC; Davey V; Kovacs JA; Feinberg J; Metcalf JA; Herpin B; Walker R; Deyton L; Davey RT; Falloon J
    Ann Intern Med; 1990 Jun; 112(11):805-11. PubMed ID: 1971503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial.
    Katabira ET; Sewankambo NK; Mugerwa RD; Belsey EM; Mubiru FX; Othieno C; Kataaha P; Karam M; Youle M; Perriens JH; Lange JM
    Sex Transm Infect; 1998 Aug; 74(4):265-70. PubMed ID: 9924466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of recombinant interferon-alpha in human immunodeficiency virus (HIV)-infected individuals.
    Rivero J; Limonta M; Aguilera A; Fraga M; López Saura P
    Biotherapy; 1994; 8(1):23-31. PubMed ID: 7547078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: effects of low-dose, sublingual use of human interferon-alpha.
    Russell IJ; Vipraio GA; Michalek JE; Craig FE; Kang YK; Richards AB
    J Interferon Cytokine Res; 1999 Aug; 19(8):969-78. PubMed ID: 10476945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An interim report on the effect of natural human interferon alpha (IFN-alpha) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1).
    Babiuch L; Mian M; Kamińska E; Szymańska B; Georgiades JA
    Arch Immunol Ther Exp (Warsz); 1993; 41(3-4):213-9. PubMed ID: 7907465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of interferon alpha therapy for HIV type 1 infection.
    Haas DW; Lavelle J; Nadler JP; Greenberg SB; Frame P; Mustafa N; St Clair M; McKinnis R; Dix L; Elkins M; Rooney J
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):183-90. PubMed ID: 10710206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients.
    Nguyen BY; Clerici M; Venzon DJ; Bauza S; Murphy WJ; Longo DL; Baseler M; Gesundheit N; Broder S; Shearer G; Yarchoan R
    AIDS; 1998 May; 12(8):895-904. PubMed ID: 9631143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, placebo-controlled, double-blind study of low-dose oral interferon-alpha in HIV-1 antibody positive patients.
    Hulton MR; Levin DL; Freedman LS
    J Acquir Immune Defic Syndr (1988); 1992; 5(11):1084-90. PubMed ID: 1357152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection.
    Schnittman SM; Vogel S; Baseler M; Lane HC; Davey RT
    J Infect Dis; 1994 May; 169(5):981-9. PubMed ID: 7909550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity.
    Skillman DR; Malone JL; Decker CF; Wagner KF; Mapou RL; Liao MJ; Testa D; Meltzer MS
    J Infect Dis; 1996 May; 173(5):1107-14. PubMed ID: 8627061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection.
    Frissen PH; Brinkman K; Ten Napel CH; van der Ende IM; van Buuren IA; Boucher CA; Reiss P; Lange JM
    Antivir Ther; 1996 Apr; 1(2):89-97. PubMed ID: 11321184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
    Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
    Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
    Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
    Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1).
    Koech DK; Obel AO; Minowada J; Hutchinson VA; Cummins JM
    Mol Biother; 1990 Jun; 2(2):91-5. PubMed ID: 1973045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia.
    Villamor N; Reverter JC; Montserrat E; Urbano-Ispízua A; Vives-Corrons JL; Rozman C
    Leukemia; 1992 Jun; 6(6):547-52. PubMed ID: 1376376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.